Pfizer lifts profit forecast on strong sales of cancer, heart drugs
Adds price negotiation details, paragraphs 8-10, RSV in paragraphs 19-20, graphic on drug sales
By Bhanvi Satija and Michael Erman
July 30 (Reuters) -Pfizer PFE.N raised its annual profit forecast on Tuesday, helped by cancer treatments acquired through a $43 billion deal for Seagen and strong sales of its heart disease drug as the company deals with a sharp revenue drop from COVID products.
The market for Pfizer's COVID-19 vaccine and treatment has shrunk by billions of dollars a year.
Pfizer CEO Albert Bourla responded with several acquisitions, including the Seagen deal and cost-cutting measures. The New York-based drugmaker has also sharpened its focus on cancer treatments.
Investors fled from Pfizer as COVID worries declined and the company's shares are trading at around half their pandemic-era highs.
J.P. Morgan analyst Chris Schott said he expects Pfizer's stock to continue to trade in the current range due to limited revenue growth and stronger expectations for many of its rivals.
"We believe stronger new launch performance and/or further progress on the pipeline will be necessary to significantly change the narrative," he wrote in a research note.
Pfizer shares were off less than 1% at $30.44.
Sales of Eliquis, the blood thinner it shares with Bristol Myers Squibb BMY.N, are expected to be curtailed starting in 2026, when the U.S. begins using negotiated prices for some drugs for its Medicare health plan for people age 65 and over.
Pfizer executives echoed comments from other drugmakers earlier this month, saying it expects to be able to navigate the impact on Eliquis, which it sees as an important drug for the company for the foreseeable future.
Overall, the impact of the law allowing U.S. price negotiations on Pfizer "is somewhat muted as you think about it economically," Chief Financial Officer David Denton said. He said many products that could be selected for negotiation in the coming years will be nearing the end of their patent protection.
Quarterly sales grew 3% operationally to $13.3 billion, marking its first quarter of sales growth since COVID revenue peaked in late 2022.
The quarter was helped by sales of its heart disease drug, sold under brand names Vyndaqel or Vyndamax and cancer therapy Padcev.
Pfizer now expects annual profit to be in the range of $2.45 to $2.65 per share, compared with its prior profit forecast of $2.15 to $2.35 per share.
BMO Capital Markets analyst Evan Seigerman said given the company's previous conservative forecast, the increase was somewhat expected. "Still, we are encouraged to see Pfizer executing where it matters," he wrote in a research note.
Pfizer also raised its full-year sales forecast for its antiviral treatment Paxlovid for high-risk COVID cases by $500 million to $3.5 billion.
Vyndaqel sales came in $200 million ahead of analyst estimates at $1.32 billion for the quarter, according to LSEG data.
Sales of bladder and urinary tract cancer treatment Padcev were $394 million for the quarter, beating estimates of $362 million.
Quarterly sales of the COVID vaccine Pfizer makes with German partner BioNTech 22UAy.DE were $195 million, while Paxlovid sales were $251 million. Analysts were expecting sales of $176 million for Comirnaty and $247.7 million for Paxlovid.
Pfizer was disappointed with its 2023 launch of RSV shot Abrysvo, but the company expressed optimism about the vaccine in the U.S. this year.
"We've significantly strengthened our contracting position," said Pfizer's Chief U.S. Commercial Officer Aamir Malik, noting that those decisions are set to take effect in August. Last year, rival GSK GSK.L won two-thirds of the RSV vaccine market, mostly due to its contracts with retail pharmacies.
Pfizer stock performance https://reut.rs/3WmEEiF
Second-quarter sales of Pfizer's drugs https://reut.rs/4cZVJ8Z
Reporting by Bhanvi Satija and Christy Santhosh in Bengaluru and Michael Erman in New York; Editing by Anil D'Silva and Bill Berkrot
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
